The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Systems biology and combination therapy in the quest for clinical efficacy
Abstract
Combinatorial control of biological processes, in which redundancy and multifunctionality are the norm, fundamentally limits the therapeutic index that can be achieved by even the most potent and highly selective drugs. Thus, it will almost certainly be necessary to use new 'targeted' pharmaceuticals in combinations. Multicomponent drugs are standard in cytotoxic chemotherapy, but their development has required arduous empirical testing. However, experimentally validated numerical models should greatly aid in the formulation of new combination therapies, particularly those tailored to the needs of specific patients. This perspective focuses on opportunities and challenges inherent in the application of mathematical modeling and systems approaches to pharmacology, specifically with respect to the idea of achieving combinatorial selectivity through use of multicomponent drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall, these examples demonstrate the potential use of mechanistic and data driven modelling in dose selection, studies of drug-drug interaction, and identification of the most efficient therapies [338].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [338]
In the citing paper
“Accurate predictions of combination treatments from single treatment data would allow a cost-effective pre-selection of promising drug candidates for experimental follow-up, which is highly relevant for modern personalized medicine (Fitzgerald et al., 2006).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Fitzgerald et al., 2006
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561 · cited 1×
“However, growth of cells in the presence of IGF-1 was found to be unaffected when mTOR was inhibited with a rapamycin analog; instead, activity of the upstream regulator Akt increase”
BackgroundRobustness in the Strategy of Scientific Model Building
Box, G. E. P. (1979) · Robustness in Statistics · doi:10.1016/b978-0-12-438150-6.50018-2 · Cited by 1,562
Enzyme and metabolic inhibitors
Webb, J. L. (1963) · Academic Press eBooks · doi:10.5962/bhl.title.7320 · Cited by 1,514
The search for synergy: a critical review from a response surface perspective.
Greco, W. R., Bravo, G., & Parsons, J. C. (1995) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06847-4 · Cited by 1,434
Berenbaum, M. C. (1989) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00026-2 · Cited by 1,414
Cell-signalling dynamics in time and space
Kholodenko, B. N. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1838 · Cited by 1,347 · cited 1×
“However, large models with multiple signaling circuits raise new conceptual issues, such as how best to represent the partitioning of shared components (for example, Ras, MAP kinases and others) among potentially competing pathway”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314 · cited 1×
“Inhibition of mTOR is promising as an anticancer strategy, as many proteins lying upstream and downstream of mTOR are deregulated in a human cance”
Background
Cited by
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Domingo, E., Sheldon, J., & Perales, C. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05023-11 · Cited by 1,009
Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2
Caesar, L. K., & Cech, N. B. (2019) · Natural Product Reports · doi:10.1039/c9np00011a · Cited by 881
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
Yadav, B., Wennerberg, K., Aittokallio, T., & Tang, J. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.09.001 · Cited by 845
“…example, aneffective drugcombination maytarget multiple proteinsor pathways that are aberrantly activated in disease, but not in normal cells, and thus reduces the chances that a cancer will develop drug resistance by activating bypassing pathways, when compared to standard mono-therapies [1 – 3].”
Background
Metadata
- Authors
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K.
- Affiliations
- Merrimack Pharmaceuticals (United States) (US)
- Harvard University (US)
- Corresponding author
- Sorger, Peter K
- Venue
- Nature Chemical Biology
- Published
- 2006-08-18
- Volume
- 2
- Issue
- 9
- Pages
- 458-466
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W1994663540
- Cited by
- 570
- References
- 68
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 23 · 2023: 28 · 2022: 30 · 2021: 23 · 2020: 32 · 2019: 36 · 2018: 39 · 2017: 40 · 2016: 45 · 2015: 41 · 2014: 45 · 2013: 34 · 2012: 36
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50gm068762-10)
- National Institute of General Medical Sciences (GM 68762)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene Regulatory Network Analysis
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- combination therapy, systems biology, targeted therapy, therapeutic index, personalized medicine, cytotoxic chemotherapy
- MeSH terms
- Drug Therapy, Combination, Models, Biological, Feedback, Physiological, Systems Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systems biology and combination therapy in the quest for clinical efficacy. https://app.cochat.ai/papers/10.1038/nchembio817
- The paper
- Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B., & Sorger, P. K. (2006). Systems biology and combination therapy in the quest for clinical efficacy. Nature Chemical Biology. https://doi.org/10.1038/nchembio817
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.